Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03717623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Study acronym: POPULAR
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 28, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Dec 30, 2023 to Dec 30, 2025v9
  2. Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates: Jun 30, 2023 to Dec 30, 2023
    • Enrollment target: 92 to 100
    • Site details revised
    v8
  3. Primary and study completion dates: Dec 31, 2022 to Jun 30, 2023
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 92
    • Site details revised
    v7
  4. Primary completion date: Jun 30, 2021 to Dec 31, 2022
    • Study completion date: Dec 31, 2021 to Dec 31, 2022
    v6
  5. Primary completion date: Jun 30, 2020 to Jun 30, 2021
    • Study completion date: Dec 31, 2020 to Dec 31, 2021
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2019 to Aug 1, 2019
    v4
  2. Start date: Mar 2019 to May 2019v3
  3. Start date: Jan 2, 2019 to Mar 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
Trial Details
NCT Number NCT03717623
Lead Sponsor Melbourne Health
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Posaconazole, Pharmacokinetics, Invasive Candidiases, Invasive Aspergillosis, Invasive Mycosis, Fungal Infection, Prophylaxis
Related terms Candidiasis, Invasive, Invasive Fungal Infections, Mycoses
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov